Skip to main content
OpenTrials
Completed

NCT Number: NCT04993066

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus

Demonstrate the safety and efficacy of the GentleMax Pro Plus™ laser system for its intended uses: hair removal including pseudofolliculitis barbae (PFB), clearance of pigmented and/or vascular lesions, temporary increase of clear nail in patients with onychomycosis and improvement in appearance of wrinkles. Evaluate GentleMax Pro Plus™ laser system for the clearance of acne.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pseudofolliculitis Barbae Acne Acne Vulgaris Acneiform Eruptions Bacterial Infections and Mycoses Dermatomycoses Infections Mycoses Nail Diseases Onychomycosis Pigmented Lesions Sebaceous Gland Diseases Skin Diseases Skin Diseases, Infectious Skin and Connective Tissue Diseases Tinea Unwanted Hair Vascular Lesion Wrinkle

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Candela Institute of Excellence

Marlborough, Massachusetts, 01752, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age or older
  • Willingness to provide signed, informed consent to participate in the study
  • Presence of unwanted hair, moderate or greater benign pigmented lesions, active acne, vascular lesions, nails affected with onychomycosis, and/or wrinkles assessed as Fitzpatrick Wrinkle and Elastosis Score (FWS) >/= 1
  • Willingness to adhere to study treatment and follow-up schedule
  • Willingness to adhere to post-treatment care instructions
  • Willingness to allow photographs and/or video of treated areas, and to release their use for scientific/educational and/or promotional/marketing purposes
  • Willing to abstain from any other procedures, medications or topicals in the study treatment areas for the duration of the study which the investigator deems would interfere with the study

Exclusion criteria

  • Pregnant, planning pregnancy during the study, or breast feeding
  • Blonde, grey, or white hair in subjects seeking hair removal
  • Tattooed skin in the intended treatment area
  • Active sun tan in the intended treatment area
  • History of active Herpes Virus Simplex (HSV) or similar condition in the intended treatment area unless treated with prophylactic medication
  • History of melanoma
  • History of vitiligo in the intended treatment area
  • History of keloid or hypertrophic scar formation
  • History of Melasma in the intended treatment area or per Investigator's discretion
  • Severe immunosuppression resulting from medications and/or a medical condition that could impair healing after treatment
  • Open wound or infection in the intended treatment area
  • History of light induced seizure disorders
  • The subject is not suitable, in the opinion of the Investigator, for participation in the study due to inability to adhere to the study requirements, medical, or other reasons that could compromise the study integrity or subject safety
  • Dermatologic and/or cosmetic procedures including use of medications, or topicals in the intended treatment area(s) during a timepoint prior to the study that the investigator deems the subject unsuitable for the study

Treatment and study plan

GentleMax Pro Plus

Device

The GentleMax Pro Plus laser system to be used in this study received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) under K201111 on May 26, 2020

Primary outcomes

  1. Treatment Time

    Time frame: 8 Months

    Evaluate the speed (time of treatment completion) with larger spot sizes for hair removal

  2. Hair Count Assessments

    Time frame: 14 Months

    Improvement in hair clearance quantified by hair counts taken within a portion of the treatment area and percent reduction by assessments of digital photos taken at Baseline compared to follow-ups.

  3. Global Aesthetic Improvement Score

    Time frame: 7 Months

    Improvement in the appearance of wrinkles, benign pigmented lesions, and/or vascular lesions from baseline to follow-up(s) via the Investigator Global Aesthetic Improvement Score (IGAIS) whereas 1 = very much improved and 5 = worse. A lower score post treatment(s) indicates a better outcome.

  4. Fitzpatrick Wrinkle and Elastosis Score

    Time frame: 7 Months

    Improvement in the appearance of wrinkles from baseline to follow-up(s) via the Investigator Fitzpatrick Wrinkle and Elastosis Scale whereas 1 = fine wrinkles and mild elastosis and 9 = deep wrinkles and severe elastosis. A lower score post treatment(s) indicates a better outcome.

  5. Pigment Improvement Score

    Time frame: 7 Months

    Improvement in BPLs from baseline to follow-ups via the Investigator Pigment Improvement Score (PIS) whereas 0 = no improvement and 4 = excellent response. A higher score post treatment(s) indicates a better outcome.

  6. Acne Counts

    Time frame: 5 Months

    Measured by improvement of acne counts from baseline compared to follow-ups. A lower score post treatment(s) indicates a better outcome.

  7. Onychomycosis Score

    Time frame: 9 Months

    Improvement in the appearance of nails from Baseline to follow-up(s) via the Scoring Clinical Index of Onychomycosis (SCIO Index) which ranges from 0 to 30 whereas 0 indicates lesser degree of onychomycosis and 30 indicates higher degree of onychomycosis. A lower score post treatment(s) indicates a better outcome.

  8. Onychomycosis Score

    Time frame: 9 Months

    Improvement in the appearance of nails from Baseline to follow-up(s) via the Onychomycosis Improvement Scale whereas 1 = completely cleared and 5 = worse. A lower score post treatment(s) indicates a better outcome.

Secondary outcomes

  1. Subject Satisfaction Score

    Time frame: 24 Months

    Overall subject satisfaction with study treatments per treatment indication as measured by Subject Satisfaction Scale whereas 1 = not satisfied and 5 = very satisfied. A higher score post treatment(s) indicates a better outcome.

  2. Subject Global Aesthetic Improvement Score

    Time frame: 24 Months

    Overall subject improvement with study treatments per treatment indication as measured by Subject Global Aesthetic Improvement Score (SGAIS) whereas 1 = very much improved and 5 = worse. A lower score post treatment(s) indicates a better outcome.

  3. Subject Pain

    Time frame: 8 Months

    Measurement of Subject Pain Assessment post-treatment for all subjects, using an 11-point pain Numerical Rating Scale where 0=no pain, 10=extreme pain

Sponsors and collaborators

Lead sponsor

Candela Corporation

Industry

Registry information

Official study title

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro/ GentleMax Pro Plus

Important dates

Study start
2020
Primary completion
2022
Study completion
2023
First posted
Aug 6, 2021
Registry last updated
Nov 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.